Dr. Melotek on Cetuximab Added to Chemotherapy and Chemoradiation in Head and Neck Cancer

Share it with your friends Like

Thanks! Share it with your friends!


James Melotek, MD, Radiation and Cellular Oncology, University of Chicago Medicine, discusses an analysis of a phase II study examining the addition of cetuximab to induction chemotherapy and accelerated or hyperfractionated chemoradiation therapy for locoregionally advanced head and neck cancer.


Write a comment